These findings in patient-derived NSCLC cells supported MUC1-C dependence for activation of a memory pathway that is mediated by STAT1 and drives resistance to osimertinib and other TKI inhibitors. This evidence concerns the gene STAT1 and non-small cell lung carcinoma.